SCHEMBL6094110

SCHEMBL6094110

CC[C@H](NC(=O)c1nc(N2CCCCS2(O)O)n(C)c(=O)c1O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 9/20 0.41
KCNK3 O14649 8/20 0.41
TACR2 P21452 4/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
OPRM1 P35372 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
TACR1 P25103 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6094529 1.00 TACR3 (0.41) TACR3KCNK3TACR2ALDH1A1KDM4E
SCHEMBL6094206 0.91 CALCA (0.39) TACR3ALDH1A1HTT
SCHEMBL6094517 0.91 CALCA (0.43) TACR3KCNK3TACR2ALDH1A1KDM4E
SCHEMBL6094100 0.91 CALCA (0.43) TACR3KCNK3TACR2ALDH1A1KDM4E
SCHEMBL6095839 0.88 ALDH1A1 (0.45) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL6095305 0.88 ALDH1A1 (0.45) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL6095732 0.85 CALCA (0.36) ALDH1A1KDM4ELMNAHTT
SCHEMBL6095728 0.85 CALCA (0.36) ALDH1A1KDM4ELMNAHTT
SCHEMBL6096403 0.85 CALCA (0.41) KDM4ELMNATACR1
SCHEMBL6094202 0.82 CALCA (0.46) TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US claimed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US claimed
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US disclosed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204498-A1 HIV integrase inhibitors IMPDH1, TYMP, REV1 TACR3 4699/4885KCNK3 4677/4885TACR2 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.